FDA Warning Letters of March 31, 2026: Seven Research-Peptide Sellers

Updated August 21, 2026

On March 31, 2026, the U.S. Food and Drug Administration signed warning letters to seven sellers of research peptides, posting all seven to its public index on April 7, 2026. Two findings recur through the batch: therapeutic-effect descriptions of the compounds, and supplies for administration listed in the same cart as the compounds themselves.

Batch record

The seven letters, by letter number

One clerical note for researchers matching press coverage to this table: "Guangzhou Huli Technology" and "Fantasy Face" are not two recipients. They are the registered name and the dba on a single letter, 722228 — some secondary summaries have listed them separately.

Documented findings

Two patterns recur across the batch, per the letters and contemporaneous regulatory coverage. The first is descriptive: product-page language characterizing what a compound does in a human subject, appearing beside research-use disclaimers. The second is structural: checkouts offering administration supplies alongside the compounds. In the letters, the composition of the cart is itself cited as evidence of intended use — no written claim is required for the pairing to enter the record.

The agency's position on research-use disclaimers

The letters address the disclaimer question directly. FDA's stated position, quoted from the batch: despite research-use-only disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use."

Coded product names

Several recipients listed compounds under coded designations in place of standard nomenclature — coverage of the batch documents "GLP-1 SM" and "GLP-3 RT" as the examples. Per the letters, the agency read the coding as circumvention, not caution: marketing a recognized drug class while avoiding the terms that would identify it.

Position in the enforcement record

Seven letters in one day is the largest single-date warning-letter action against research-peptide sellers recorded by this index; the December 10, 2024 action named four entities. The batch's place in the wider sequence of raids, pleas, closures, and sentencing is tabulated in the enforcement chronology. The December 2024 record for Summit Research Peptides documents the same aggregate-evidence method applied to a company's social-media post, and every recipient entity is indexed in the vendor hub.

Related records on this index

• Marketplace storefronts in this batch — two letters open on eBay store reviews, with the platform notified
• Patch and oral products in the enforcement record
• Linked off-site content attributed to the vendor
• Study citations did not move copy out of evidence — cross-batch record
• What follows a warning letter — the documented process

Sources

1. FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
2. FDA Warning Letter, Mile High Compounds LLC, 721600-03312026. fda.gov
3. FDA Warning Letter, Gram Peptides, 721806-03312026. fda.gov
4. FDA Warning Letters index (Prime Sciences 721805; PekCura Labs 721709; FormPour 722215; Guangzhou Huli Technology dba Fantasy Face 722228). fda.gov
5. Policy Canary analysis of the batch. policycanary.io
6. Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org

Further reading

• FDA peptide warning letters April 2026: the seven-letter batch — Artemis Labs store article on the same batch.

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.